


The logo for RADemics, featuring a dark blue vertical bar on the left and a blue arrow pointing right with the text "RADemics" inside.

RADemics

Lung Cancer Prediction and Imaging Analytics Using AI

An abstract graphic consisting of several thin, curved lines in dark blue and light grey, originating from the bottom left and extending upwards and to the right.

S. Dharanika, P. Selvaraju

ST. JOSEPH'S COLLEGE OF ENGINEERING, EXCEL
ENGINEERING COLLEGE

Lung Cancer Prediction and Imaging Analytics Using AI

¹S. Dharanika, Assistant professor, Department of Artificial Intelligence and Data Science, St. Joseph's College of engineering, Chennai, Tamil Nadu, India. dharanika@stjosephs.ac.in

²P. Selvaraju, Associate Professor, Department of Computer Science and Engineering, Excel Engineering College, Komarapalayam, Tamil Nadu, India. rpselvaraju@gmail.com

Abstract

Lung cancer continues to represent one of the most critical healthcare challenges worldwide due to high mortality rates, delayed diagnosis, tumor heterogeneity, and limitations associated with conventional screening and diagnostic procedures. Rapid advancements in Artificial Intelligence (AI), machine learning, deep learning, and imaging analytics have introduced significant opportunities for improving early-stage lung cancer detection, tumor characterization, prognosis prediction, and personalized therapeutic planning. Integration of advanced computational intelligence with multimodal medical imaging modalities such as Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), and digital histopathology supports automated pulmonary nodule detection, segmentation, classification, radiomic feature extraction, and predictive analytics with improved diagnostic precision and clinical reliability. This book chapter presents a comprehensive exploration of AI-driven lung cancer prediction and imaging analytics through detailed analysis of convolutional neural networks, transfer learning frameworks, hybrid deep learning architectures, radiomics analytics, multimodal imaging integration, and explainable artificial intelligence techniques for clinical decision support. Critical emphasis focuses on classification frameworks, predictive modeling systems, imaging biomarker analysis, survival prediction, treatment response evaluation, and precision oncology applications capable of supporting intelligent healthcare environments. Emerging technologies involving federated learning, cloud-assisted healthcare analytics, edge computing, and multimodal fusion architectures receive substantial attention for scalable, privacy-preserving, and real-time diagnostic applications. The chapter also critically examines major research challenges associated with limited annotated datasets, computational complexity, model interpretability, ethical governance, data privacy, and clinical generalization across heterogeneous healthcare infrastructures. Explainable AI methodologies including Grad-CAM, SHAP analysis, and saliency mapping contribute enhanced transparency and trustworthiness during automated diagnostic interpretation and clinical validation procedures. Radiomics-driven precision medicine frameworks demonstrate substantial capability for individualized treatment planning through quantitative imaging biomarker analysis and radiogenomic integration. Continuous progress in artificial intelligence-driven imaging analytics establishes intelligent diagnostic systems as a transformative paradigm for improving diagnostic accuracy, optimizing therapeutic decision-making, reducing radiological variability, and enhancing patient-specific lung cancer management within next-generation precision healthcare ecosystems.

Keywords: Lung Cancer Prediction, Artificial Intelligence, Deep Learning, Radiomics Analytics, Medical Imaging, Precision Oncology

Introduction

Lung cancer represents one of the most severe and rapidly increasing public health concerns across the global healthcare landscape due to its high incidence, mortality burden, and complex clinical characteristics. Among various forms of cancer, lung malignancies account for a substantial proportion of cancer-related deaths because diagnosis frequently occurs during advanced stages of disease progression [1]. Delayed clinical identification significantly reduces therapeutic effectiveness and survival outcomes, creating urgent demand for advanced diagnostic methodologies capable of supporting early-stage detection and accurate prognostic evaluation [2]. Several environmental and biological factors contribute toward lung cancer development, including tobacco exposure, industrial pollutants, genetic abnormalities, occupational carcinogens, and long-term respiratory complications [3]. Rapid urbanization and increasing environmental contamination have also intensified respiratory disease prevalence within industrialized and developing regions. Conventional diagnostic procedures primarily depend on radiological examination, histopathological assessment, and physician interpretation, leading to considerable diagnostic variability and increased workload within clinical oncology departments [4]. Complex tumor morphology, overlapping anatomical structures, subtle pulmonary nodules, and image noise often complicate radiological interpretation during routine screening procedures. Such limitations create significant challenges for radiologists during differentiation between benign abnormalities and malignant lesions. Continuous expansion of medical imaging repositories generated from modern healthcare systems has accelerated demand for intelligent computational frameworks capable of supporting automated image analysis, predictive diagnostics, and personalized therapeutic planning. Consequently, artificial intelligence-driven healthcare analytics has emerged as a transformative research domain for improving clinical accuracy, diagnostic efficiency, and patient-specific oncology management within next-generation medical environments [5].

Medical imaging technologies play a fundamental role in lung cancer screening, disease staging, treatment planning, and therapeutic response evaluation through detailed visualization of thoracic structures and pulmonary abnormalities. Imaging modalities such as Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, and digital histopathological imaging generate large-scale multidimensional datasets suitable for computational analysis and predictive interpretation [6]. Low-dose Computed Tomography screening programs contribute significantly toward early pulmonary nodule detection through high-resolution anatomical imaging capable of identifying suspicious lesions during asymptomatic disease stages. Positron Emission Tomography supports metabolic characterization of malignant tissue through radiotracer-based functional imaging, enabling identification of tumor aggressiveness and metastatic spread [7]. Magnetic Resonance Imaging provides enhanced soft tissue contrast and supports evaluation of thoracic invasion, vascular involvement, and metastatic progression. Histopathological imaging contributes microscopic cellular characterization through digital pathology analysis and tumor grading procedures [8]. Integration of multiple imaging modalities strengthens diagnostic reliability through comprehensive assessment of structural, functional, and pathological tumor characteristics. Continuous growth in imaging data complexity and volume has created substantial challenges for manual clinical interpretation and radiological consistency [9]. Variability in image acquisition protocols, scanner characteristics, annotation procedures, and physician expertise frequently affects diagnostic precision across healthcare institutions. Automated computational systems capable of processing heterogeneous imaging

datasets therefore represent a critical requirement for improving clinical workflow efficiency and reducing diagnostic uncertainty within modern oncology practice [10].